A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease

Nature Communications

Volumn 6, Issue , 2015, Pages

  Ahmad, Omar S ^a,b   Morris, John A ^a,b   Mujammami, Muhammad ^a,b   Forgetta, Vincenzo ^a,b   Leong, Aaron ^c   Li, Rui ^a,b   Turgeon, Maxime ^b   Greenwood, Celia M T ^b   Thanassoulis, George ^b   Meigs, James B ^c   Sladek, Robert ^b   Richards, J Brent ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; DIABETES; ESTIMATION METHOD; GENETIC VARIATION; GLUCOSE; HEALTH RISK;

ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; ADULT; AGED; CASE CONTROL STUDY; CAUSALITY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; ODDS RATIO;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CAUSALITY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84930667824     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8060     Document Type: Article

References (58)

1. Gore, M. O. & McGuire, D. K. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): Cardiovascular observations in context. Diab. Vasc. Dis. Res. 6, 53-55 (2009).
2. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215-2222 (2010).
3. Bhattacharyya, O. K., Shah, B. R. & Booth, G. L. Management of cardiovascular disease in patients with diabetes: The 2008 Canadian Diabetes Association guidelines. Can. Med. Assoc. J. 179, 920-926 (2008).
4. Coutinho, M., Gerstein, H. C., Wang, Y. & Yusuf, S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22, 233-240 (1999).
5. Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
6. Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
7. ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
8. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319-328 (2012).
9. Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 373, 1765-1772 (2009).
10. Gerstein, H. C. et al. Effects of intensive glycaemic control on ischaemic heart disease: Analysis of data from the randomised, controlled ACCORD trial. Lancet 384, 1936-1941 (2014).
11. Cheng, A. Y. & Lau, D. C. The Canadian Diabetes Association 2013 clinical practice guidelines-raising the bar and setting higher standards! Can. J. Diabetes 37, 137-138 (2013).
12. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2013. Diabetes Care 36 (Suppl 1), S4-10 (2013).
13. Havas, S. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: Time to challenge conventional wisdom. Arch. Intern. Med. 169, 150-154 (2009).
14. Shaw, J. E., Sicree, R. A. & Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87, 4-14 (2010).
15. Mendis, S., Puska, P. & Norrving, B. (eds). Global Atlas on Cardiovascular Disease Prevention and Control, 2 (World Health Organization, the World Heart Federation and the World Stroke Organization, 2011).
16. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 31, 596-615 (2008).
17. Fewell, Z., Davey Smith, G. & Sterne, J. A. C. The impact of residual and unmeasured confounding in epidemiologic studies: A simulation study. Am. J. Epidemiol. 166, 646-655 (2007).
18. Laakso, M. & Kuusisto, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10, 293-302 (2014).
19. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 37 (Suppl 1), S14-S80 (2014).
20. Timpson, N. J., Wade, K. H. & Smith, G. D. Mendelian randomization: Application to cardiovascular disease. Curr. Hypertens. Rep. 14, 29-37 (2012).
21. Palmer, T. M. et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat. Methods Med. Res. 21, 223-242 (2012).
22. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37, 658-665 (2013).
23. Burgess, S. & Thompson, S. G. Use of allele scores as instrumental variables for Mendelian randomization. Int. J. Epidemiol. 42, 1134-1144 (2013).
24. Scott, R. A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat. Genet. 44, 991-1005 (2012).
25. Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981-990 (2012).
26. Voight, B. F. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 579-589 (2010).
27. CARDIoGRAMplusC4D Consortium et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 45, 25-33 (2013).
28. Schunkert, H. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 43, 333-338 (2011).
29. Cotsapas, C. et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 7, e1002254 (2011).
30. Johnson, A. D. et al. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938-2939 (2008).
31. Patsopoulos, N. A., Evangelou, E. & Ioannidis, J. P. Sensitivity of between-study heterogeneity in meta-analysis: Proposed metrics and empirical evaluation. Int. J. Epidemiol. 37, 1148-1157 (2008).
32. Dimas, A. S. et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63, 2158-2171 (2014).
33. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27, 1133-1163 (2008).
34. Smith, G. D. & Ebrahim, S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1-22 (2003).
35. Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G. & Richards, J. B. Mendelian randomisation applied to drug development in cardiovascular disease: A review. Journal of medical genetics jmedgenet 52, 71-79 (2014).
36. Benn, M. et al. Nonfasting glucose, ischemic heart disease, and myocardial infarction. J. Am. Coll. Cardiol. 59, 2356-2365 (2012).
37. Adams, J. N. et al. Analysis of common and coding variants with cardiovascular disease in the Diabetes Heart Study. Cardiovasc. Diabetol. 13, 77 (2014).
38. Jansen, H., Samani, N. J. & Schunkert, H. Mendelian randomization studies in coronary artery disease. Eur. Heart J. 35, 1917-1924 (2014).
39. Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380, 572-580 (2012).
40. Zacho, J. et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897-1908 (2008).
41. Van Meurs, J. B. et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am. J. Clin. Nutr. 98, 668-676 (2013).
42. Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., Grande, P. & Tybjaerg-Hansen, A. Genetically elevated bilirubin and risk of ischaemic heart disease: Three Mendelian randomization studies and a meta-analysis. J. Intern. Med. 273, 59-68 (2013).
43. Palmer, T. M. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. Br. Med. J. 347, f4262-f4262 (2013).
44. Lieb, W. et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension 61, 995-1001 (2013).
45. Linsel-Nitschke, P. et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease-A Mendelian randomisation study. PLoS ONE 3, e2986 (2008).
46. Haase, C. L., Tybjaerg-Hansen, A., Grande, P. & Frikke-Schmidt, R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J. Clin. Endocrinol. Metab. 95, E500-E510 (2010).
47. Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345-1352 (2013).
48. Jørgensen, A. B. et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 34, 1826-1833 (2013).
49. Fall, T. et al. The role of adiposity in cardiometabolic traits: A Mendelian randomization analysis. PLoS Med. 10, e1001474 (2013).
50. Dastani, Z. et al. The shared allelic architecture of adiponectin levels and coronary artery disease. Atherosclerosis 229, 145-148 (2013).
51. Yaghootkar, H. et al. Mendelian randomisation studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62, 3589-3598 (2013).
52. Bao, W. et al. Predicting risk of type 2 diabetes mellitus with genetic risk models on the basis of established genome-wide association markers: A systematic review. Am. J. Epidemiol. 178, 1197-1207 (2013).
53. Vassy, J. L. et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes 63, 2172-2182 (2014).
54. Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
55. Ehret, G. B. et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103-109 (2011).
56. Randall, J. C. et al. Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet. 9, e1003500 (2013).
57. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557-560 (2003).
58. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002).